Zhang Jie, Gan Huilin, Duan Xiaoyan, Li Guangming
Department of Gastroenterology, Xinhua Hospital, School of Medicine, Shanghai Jiaotong University, Yangpu District, Shanghai 200092, China.
Biomedicines. 2024 Oct 15;12(10):2340. doi: 10.3390/biomedicines12102340.
Over the past decade, there has been a rapid increase in the incidence of inflammatory bowel disease. It has been suggested that multifactorial interactions of environmental factors, genetic factors, immune response and intestinal microbiota are involved in the pathogenesis of inflammatory bowel disease. It is widely recognized that the intestinal microbiota are essential for human metabolism, the immune system and pathogen resistance, and are integral to human health. Therefore, the dysbiosis of the microbiota is a critical step leading to intestinal mucosal damage and a key factor in the pathogenesis of inflammatory bowel disease. Regulating the microbiota through interventions such as enteral nutrition, fecal microbiota transplantation, and probiotic supplementation has the potential to prevent or even reverse intestinal dysbiosis, opening up new perspectives for the treatment of inflammatory bowel disease.
在过去十年中,炎症性肠病的发病率迅速上升。有人提出,环境因素、遗传因素、免疫反应和肠道微生物群的多因素相互作用参与了炎症性肠病的发病机制。人们普遍认识到,肠道微生物群对人体代谢、免疫系统和病原体抵抗至关重要,是人类健康不可或缺的一部分。因此,微生物群失调是导致肠道黏膜损伤的关键步骤,也是炎症性肠病发病机制中的一个关键因素。通过肠内营养、粪便微生物群移植和补充益生菌等干预措施来调节微生物群,有可能预防甚至逆转肠道失调,为炎症性肠病的治疗开辟新的前景。